Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 18/20 | 0.46 |
| ▸ | STS | P08842 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172782 | 0.89 | CYP19A1 (0.45) | CYP19A1STSCA2 | |
| SCHEMBL10172786 | 0.87 | CYP19A1 (0.50) | CYP19A1STSCA2 | |
| SCHEMBL10172822 | 0.82 | CYP19A1 (0.46) | CYP19A1STSCA2 | |
| SCHEMBL10172576 | 0.78 | CYP19A1 (0.63) | CYP19A1STS | |
| SCHEMBL10172788 | 0.77 | CYP19A1 (0.51) | CYP19A1STSCA2 | |
| SCHEMBL10172785 | 0.77 | CYP19A1 (0.51) | CYP19A1STSCA2 | |
| SCHEMBL10172727 | 0.77 | CYP19A1 (0.62) | CYP19A1STS | |
| SCHEMBL10172573 | 0.73 | CYP19A1 (0.67) | CYP19A1STSCA2 | |
| SCHEMBL10172787 | 0.73 | CYP19A1 (0.69) | CYP19A1STSCA2 | |
| SCHEMBL10172813 | 0.70 | CYP19A1 (0.65) | CYP19A1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885STS 1844/4885CA2 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.